SCHEMBL2660132

SCHEMBL2660132

[CH]=CC(=O)N(C)C1CCN(C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.40
HTR2A P28223 4/20 0.39
HTR2C P28335 4/20 0.39
DRD2 P14416 2/20 0.39
HTR2B P41595 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
KDM4E B2RXH2 3/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.37
BRD4 O60885 1/20 0.36
TAF1 P21675 1/20 0.36
CECR2 Q9BXF3 1/20 0.36
MITF O75030 1/20 0.35
HTT P42858 1/20 0.35
RAD52 P43351 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.34
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539694 0.89 MCHR1 (0.40) HTR2AHTR2CDRD2HTR2BSIGMAR1
SCHEMBL2660134 0.81 ALDH1A1 (0.41) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL10177496 0.80 HTR2A (0.41) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL21872281 0.80 HTR2A (0.41) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL19502747 0.79 ALDH1A1 (0.40) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL21872282 0.79 HTR2A (0.40) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL8282498 0.76 ALDH1A1 (0.45) ALDH1A1LMNAHTR2AHTR2CKDM4E
SCHEMBL805270 0.76 LMNA (0.51) ALDH1A1LMNAHTR2AHTR2CKDM4E
SCHEMBL10147271 0.76 HTR2A (0.39) ALDH1A1LMNAHTR2AHTR2CDRD2
SCHEMBL800697 0.76 HTT (0.45) ALDH1A1LMNAHTR2AHTR2CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US disclosed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US disclosed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP disclosed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB1, GABRA5, GABRB2 ALDH1A1 541/4885LMNA 4662/4885HTR2A 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.